Recursion Pharmaceuticals, Inc.
RXRX
$3.39
-$0.03-0.88%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.06% | -89.42% | -73.14% | -62.31% | -41.33% |
| Total Depreciation and Amortization | 129.36% | 148.18% | 101.20% | 72.71% | 49.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 52.99% | 133.99% | 146.95% | 114.60% | 73.49% |
| Change in Net Operating Assets | 129.27% | 100.54% | 144.24% | 74.06% | 6.96% |
| Cash from Operations | -3.52% | -38.81% | -15.54% | -22.75% | -24.81% |
| Capital Expenditure | 52.76% | 54.90% | -1.83% | 33.94% | -14.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 390,387.32% | 390,387.32% | 14,927.33% | 14,927.33% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -78.03% | -88.48% | -35.77% | -9,162.50% | -2,763.25% |
| Cash from Investing | -106.49% | 1,552.78% | 1,986.00% | 2,348.00% | 2,642.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -89.75% | -175.60% | -1,006.36% | -741.28% | -479.63% |
| Issuance of Common Stock | 72.72% | 9.11% | -57.11% | 120.58% | 118.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 71.49% | 6.96% | -59.83% | 117.44% | 117.02% |
| Foreign Exchange rate Adjustments | 629.77% | 6,471.05% | 3,459.45% | 5,775.86% | -1,911.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -25.15% | 498.89% | -22.50% | 215.20% | 227.85% |